Contents
Contents
A pharmacy license and compounding authority address permission to prepare and dispense; insurance claim coverage depends on the payer’s benefit, the pharmacy’s participation, the ingredients and what was actually dispensed. If you work in a pharmacy, you may see the prescription, the preparation and the billing from different sides of the same transaction. A license on the wall cannot explain why the claim describes a different product from the one prepared for the patient.
The pharmacy filling the prescription must be identifiable in the license, preparation and shipment records. A state pharmacy license covers the named pharmacy and premises. Permission to dispense into another state and permission to compound sterile drugs are separate questions.
California’s July 2026 pharmacy lawbook requires a pharmacy license for each pharmacy and separate premises, addresses nonresident dispensing into California, and separately licenses sterile compounding. An interstate order connects the filling location and the destination, each with its own authority question.
For an insider, the connection runs from the dispensing entity and location to the prescription and shipment. The records that matter identify which pharmacy handled this prescription, where it prepared the medicine and where it sent it. We compare those records with the permissions the pharmacy held and what its claim told the payer.
Patient-specific compounding centers on an identified patient’s prescription. The federal outsourcing-facility category allows production with or without prescriptions for identified patients.
The patient-specific route sits within the Federal Food, Drug, and Cosmetic Act. It covers qualifying compounding by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a licensed physician.
Under that law, a prescriber can determine that a change makes a significant difference for the patient compared with an available commercial drug. That difference matters to whether the compound counts as a copy. The ingredient purchase, prescription and resulting preparation each describe part of that work.
The outsourcing-facility framework covers registered facilities engaged in sterile compounding, with compounding performed by or under the direct supervision of a licensed pharmacist. Its federal registration and the state permissions for the work are distinct records.
Registration identifies the facility and its location. Drug reporting identifies ingredients and production, while the label connects the product to its lot or batch. Those records let us trace the preparation back to the facility that made it.
Drug Enforcement Administration registration authorizes controlled-substance activities within the registration’s scope. The Controlled Substances Act generally requires separate registration at each principal place of business where controlled substances are manufactured, distributed or dispensed.
For a pharmacy handling controlled prescriptions, the registration, prescription and dispensing records must be connected to that location. The health care program’s coverage and payment records then supply the payer side of the transaction.
Accreditation assesses capabilities under an accreditor’s standards. Payer enrollment establishes participation in the applicable public program. A pharmacy benefit manager or plan network agreement sets participation, reimbursement and service terms.
That distinction matters in specialty pharmacy, where access to a manufacturer’s limited-distribution product and access to the patient’s reimbursable pharmacy network are separate. Accreditation can sit alongside both. A pharmacy’s ability to obtain the product and the patient’s ability to use that pharmacy under the benefit need to line up.
The practical comparison is between the entity and site named in the credentials and the entity billing under the network agreement. Whether the patient’s prescription is covered comes from the benefit and the transaction. We keep those documents connected to the same pharmacy, product and period.
A compounding pharmacy insurance claim is payable when it meets the applicable benefit and payment requirements for the prescription actually furnished. The answer depends on the payer, the covered ingredients, the pharmacy’s participation and any required authorization.
In its January 2016 drug-benefit manual, the Centers for Medicare & Medicaid Services says a compound can qualify for Part D coverage only if it contains at least one ingredient that independently meets the Part D drug definition and no ingredient covered under Part B as prescribed and dispensed or administered. Only costs associated with qualifying Part D components are allowable drug costs.
The same guidance distinguishes bulk powders used as active pharmaceutical ingredients from qualifying Part D drug products. Bulk powders are not covered under Part D. Mixing labor for a compound containing a qualifying component can be included in the dispensing fee.
For the compound to count as on-formulary, all its ingredients that independently qualify as Part D drugs must be on-formulary. The manual also addresses transition fills and approved exceptions for off-formulary compounds.
An ingredient name alone can hide the decisive difference. The purchasing record identifies the product the pharmacy bought. The preparation identifies what went into the compound. The claim identifies what the payer was asked to cover. The National Drug Code, quantity and prescription reference help connect those records. We examine the applicable program and contract for the dispensing period, including Medicare, Medicaid or TRICARE when that program paid the claim.
A paid claim records a payment decision. The dispensing, pickup or delivery records show what happened to the medicine. The original claim, rejection, override, reversal, rebill and final remittance tell the financial story across its changes.
The Centers for Medicare & Medicaid Services makes the consequence clear in its guidance on corrections after the point of sale. When a pharmacy bills for a drug that was never dispensed, the sponsor should recover the cost and delete the prescription drug event. When the dispensing was correct but the claim identified the wrong drug, the claim and the event record must be corrected to match what was dispensed.
The prescription drug event record is itself a summary extract. The agency’s guide to Part D data distinguishes it from the individual pharmacy claim transaction. A pharmacy reversal and a sponsor’s correction of that extract are therefore different records to connect.
For a compound, that comparison reaches back to the ingredients and forward to the final payment. The prescription, preparation record, quantity dispensed and claim should describe the same medicine. If stock was returned or billing changed, the later records matter alongside the first approval. The payment screen is only one view of the transaction.
Professional Compounding Centers of America sold ingredients and bases, including creams and gels, to compounding pharmacies. A whistleblower brought the case, and the government joined it. The government’s 2021 complaint alleged that PCCA reported inflated average wholesale prices and used the resulting TRICARE reimbursement to sell ingredients to its pharmacy customers.
The alleged sales proposition was blunt:
PCCA’s scheme was plain and direct: generate mega-spreads to increase pharmacies’ potential profits from using PCCA’s ingredients.
The complaint alleged that PCCA promoted formulas designed to maximize reimbursement and knew its pharmacy customers would bill TRICARE using its reported prices. The patient’s prescription, the supplier’s formula and the payer’s claim are where that alleged incentive becomes visible.
Fagron agreed to a $22.05 million civil settlement over allegations involving inflated ingredient prices and pharmacy billing. The Justice Department alleged that its ingredient subsidiary Freedom Pharmaceuticals set a fluticasone propionate average wholesale price of $3,500 per gram while typically selling it for approximately $160 per gram. We see the absurdity in that alleged pitch: sell the ingredient on how much taxpayer money it can bring in. The department alleged that Freedom promoted the resulting profit potential to pharmacies, whose claims reached TRICARE and the Department of Labor’s workers’ compensation programs.
Medisca’s civil settlement required a $21.75 million payment to resolve allegations involving resveratrol and mometasone furoate. The government alleged that Medisca manipulated reported prices and the difference between those prices and pharmacy acquisition costs to increase reimbursement from TRICARE and the federal employees’ compensation program.
The comparison crosses businesses: what the supplier charged, what it reported to pricing publishers, what it told the pharmacy and what the pharmacy billed. The alleged overpayments came out of taxpayer-funded healthcare benefits.
Pharmacy Place shows what a decision about dispensing authority actually decides. In its order published in October 2025, the Drug Enforcement Administration found that the Houston pharmacy filled controlled-substance prescriptions without identifying, resolving and documenting warning signs. Those included repeated prescribing patterns, high strengths or quantities, and similar prescriptions for people sharing an address.
The agency also found recordkeeping violations. It revoked the pharmacy’s controlled-substance registration and denied pending applications to renew or modify it, along with other pending applications for registration in Texas. The order took effect December 1, 2025.
That was the agency deciding whether to entrust the pharmacy with controlled-substance registration. A False Claims Act inquiry follows the payment as well: which government program paid, what the pharmacy represented, what the payment required and who knew the claim was wrong. Dispensing authority and government reimbursement each need their own evidence.
The useful evidence connects the pharmacy’s permissions to a specific preparation and payment. Credentialing staff may know the enrolled entity and approved location. Pharmacy staff may know the prescription and the preparation. Billing staff may know why a product code changed or why a reversal never reached the final payment record.
We work with insiders to connect those accounts: the license and network agreement, ingredient purchases, prescription and authorization, preparation and dispensing records, claim changes and remittance. The decisions inside the business explain how the mismatch arose and who understood it. That is where pharmacy operations become evidence about a government claim. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.
If you know the pharmacy’s credentials, the compound it prepared or why the bill changed, speak with our whistleblower experts about what the pharmacy billed. We work beside you to build your strongest case across the pharmacy’s operations and payment records, and bring in pharmacy fraud whistleblower lawyers who understand compounding and government reimbursement. You bring the inside knowledge; we bring the judgment and partnership to pursue it with you.